Flexion Therapeutics (FLXN) Upgraded by BidaskClub to “Sell”

BidaskClub upgraded shares of Flexion Therapeutics (NASDAQ:FLXN) from a strong sell rating to a sell rating in a research report sent to investors on Saturday morning.

A number of other equities analysts have also recently weighed in on the company. BMO Capital Markets lowered their price target on Flexion Therapeutics from $36.00 to $34.00 and set an outperform rating for the company in a report on Friday, January 4th. Needham & Company LLC reiterated a buy rating and set a $36.00 price target (down from $42.00) on shares of Flexion Therapeutics in a report on Friday, January 4th. Benchmark cut Flexion Therapeutics from a buy rating to a hold rating and set a $11.49 price target for the company. in a report on Friday, January 4th. Zacks Investment Research cut Flexion Therapeutics from a buy rating to a hold rating in a report on Tuesday, January 1st. Finally, Wells Fargo & Co reiterated a buy rating and set a $26.00 price target on shares of Flexion Therapeutics in a report on Friday, December 28th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. Flexion Therapeutics currently has an average rating of Hold and a consensus price target of $27.08.

Shares of FLXN opened at $13.30 on Friday. The firm has a market capitalization of $496.68 million, a price-to-earnings ratio of -3.20 and a beta of 1.54. The company has a debt-to-equity ratio of 1.02, a current ratio of 8.88 and a quick ratio of 8.74. Flexion Therapeutics has a 52-week low of $10.98 and a 52-week high of $29.10.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($1.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.09. The business had revenue of $6.99 million during the quarter, compared to analysts’ expectations of $5.93 million. Flexion Therapeutics had a negative return on equity of 88.21% and a negative net margin of 1,346.87%. On average, sell-side analysts forecast that Flexion Therapeutics will post -4.66 EPS for the current fiscal year.

In related news, insider Michael D. Clayman sold 3,278 shares of the firm’s stock in a transaction dated Thursday, January 3rd. The stock was sold at an average price of $12.36, for a total transaction of $40,516.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michael D. Clayman bought 5,000 shares of the stock in a transaction that occurred on Friday, November 9th. The shares were purchased at an average price of $17.10 per share, with a total value of $85,500.00. Following the completion of the acquisition, the insider now directly owns 83,295 shares in the company, valued at $1,424,344.50. The disclosure for this purchase can be found here. Company insiders own 14.59% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc increased its position in Flexion Therapeutics by 1.1% during the third quarter. Vanguard Group Inc now owns 1,619,112 shares of the specialty pharmaceutical company’s stock worth $30,294,000 after buying an additional 18,323 shares during the period. Vanguard Group Inc. increased its position in Flexion Therapeutics by 1.1% during the third quarter. Vanguard Group Inc. now owns 1,619,112 shares of the specialty pharmaceutical company’s stock worth $30,294,000 after buying an additional 18,323 shares during the period. Teachers Advisors LLC increased its position in Flexion Therapeutics by 27.5% during the third quarter. Teachers Advisors LLC now owns 91,180 shares of the specialty pharmaceutical company’s stock worth $1,706,000 after buying an additional 19,694 shares during the period. Macquarie Group Ltd. increased its position in Flexion Therapeutics by 10.6% during the third quarter. Macquarie Group Ltd. now owns 66,703 shares of the specialty pharmaceutical company’s stock worth $1,248,000 after buying an additional 6,399 shares during the period. Finally, MetLife Investment Advisors LLC increased its position in Flexion Therapeutics by 52.1% during the third quarter. MetLife Investment Advisors LLC now owns 23,602 shares of the specialty pharmaceutical company’s stock worth $442,000 after buying an additional 8,084 shares during the period.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

See Also: Earnings Per Share

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply